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Good distribution throughout the lung requires par- 
ticles with an aerodynamic diameter between 1 and 
5 pm (l-3) and thus most inhaled products are 
formulated with a high proportion of drug in this size 
range (4). This fraction of the emitted dose is referred 
to as either the “fine particle dose” or the “respirable 
dose”. In theory, therefore, it should be possible to 
deposit drugs throughout the lung. 
Gamma scintigraphy provides in vivo quantifi- 
cation of the dose deposited in the lung together 
with the pattern of distribution after inhalation. Two- 
(5-8) and three-dimensional (SPECT) (9,lO) imaging 
can identify the amounts of drug deposited in the 
central, intermediate and peripheral regions of the 
lung using different inhaled products. The inhaled 
products listed in Table 1 (11-13) deposit a different 
amount of drug in the lung and this could be related 
to their fine particle dose. Furthermore, it can be seen 
that, irrespective of the dose deposited, the distri- 
bution patterns in the different regions of the lung 
were very similar, and that most of the respirable 
dose (-40%) was deposited in the peripheral region 
(Table l), which has the greatest surface area. 
Borgstrom & Newman (11) studied the total depo- 
sition and distribution of terbutaline in the lung when 
delivered either via the Turbuhaler@ or a metered 
dose inhaler (MDI). This study showed that while the 
total dose deposited with the Turbuhaler@ was 
greater than with the MDI, the proportions of the 
total lung dose deposited in the different lung zones 
with both devices were very similar. 
A separate study using 13 asthma patients, 
which compared terbutaline 250 and 500,ug via a 
Turbuhaler@ or a MDI, also showed that the 
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Turbuhaler@ resulted in greater lung deposition with 
both doses (14). The amounts of drug deposited in 
the different lung regions would have been consist- 
ently smaller with the MD1 compared with the 
Turbuhaler@. This study also examined the effect of 
terbutaline 25Opg via both devices on mean increase 
in forced expiratory volume in 1 second (FEV,), and 
found that there was a greater improvement in lung 
function with the Turbuhaler@ than with the MD1 
(14). This suggests that it is likely there is a corre- 
lation between the total dose of drug deposited in the 
lung and lung function, provided the top of the 
dose-response curve is not reached. 
Formulation may also be important in drug depo- 
sition and distribution. The particle size distribution 
of chlorofluorocarbon (CFC) and hydrofluoroalkane 
(HFA) formulations of MDIs can be compared using 
cascade impactors. For the inhaled corticosteroid, 
beclomethasone dipropionate, particles emitted from 
the HFA-MD1 had a smaller particle size distribution 
(15) than those from the CFC-MD1 (4). There is a 
tendency for HFA-MDIs to contain a higher pro- 
portion of particles <2pm compared with CFC- 
MDIs. It has been suggested that such particles are 
either exhaled or are deposited in the alveoli rather 
than in the bronchial tree (1,3). Data to indicate 
whether there is any altered clinical effect from 
alveolar deposition rather than distribution through- 
out the lung are limited, but do suggest that it would 
be reduced (16-20). There may be greater systemic 
absorption from alveolar deposition (following inha- 
lation from HFA-MDIs) which could give rise to an 
increase in extra-pulmonary effects (15,21). 
Inhalation rate can also affect the dose deposited in 
the lung with some devices. Studies have shown that 
flow rate affects the fine particle dose (4,22-24). 
Salbutamol, delivered by a device that is similar to the 
Turbuhaler@ in that it has a high resistance, has been 
shown to be prone to changes in inhalation rate. 
Pitcairn et al. (25) showed that a slow inhalation rate 
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TABLE 1. Distribution of drug in the central, intermediate and peripheral zones of the lung following inhalation 
from different inhalers 
Total lung dose (%) 
Inhaler Total lung deposition (%) Central Intermediate 
MD18 10.7 26.2 31.8 
MD19 16.7 25.2 34.1 
DPI” 21.4 25.7 33.2 
Nebuliser12 9.1 37.4 22.0 
MD1 + I3 spacer 23.8 38.7 23.1 
Abbreviations: MD1 = metered dose inhaler; DPI = dry powder inhaler. 
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FIG. 1. Total lung deposition and distribution of 
salbutamol in the lung following inhalation using a 
novel device, with a high resistance. 
deposited a reduced dose in the lung compared with a 
fast rate. This study also showed that while the 
amounts of drug deposited in the lung were different 
with the two inhalation rates, distribution in the 
various lung regions was similar (Fig. 1). 
Newman et al. (26) reported that when 10 asth- 
matic patients inhaled terbutaline 5OOpg at slow 
(30 L/min) and fast (60 Wmin) rates, using a Turbu- 
hale@, significantly more drug was deposited in the 
lung using the fast rate than with the slow rate (mean 
lung deposition 16.8 vs 9.1%, respectively; PcO.01). 
There was also greater bronchodilation with the fast 
inhalation rate, but the difference was not statistically 
significant. Inter-patient variability in lung deposition 
was high, with coefficients of variation for the slow 
and fast rates of 51.6 and 48.9%, respectively. The 
difference in total lung deposition with reduced 
inhalation flow is consistent with a lower fine particle 
dose when measurements are made at a lower flow 
rate (4,22). 
Another study found a correlation between total 
dose deposited in the lung and improvement in FEV,, 
following administration of salbutamol using a 
nebuliser, a dry powder inhaler (DPI) (Rotahale@) 
and an MD1 (27). Peak expiratory flow rate (PEFR) 
and forced vital capacity (FVC) also improved in 
relation to the total drug dose deposited. This study 
also measured peripheral deposition. While a greater 
amount of drug was deposited in the peripheral 
region with the nebuliser than with the DPI, there 
were no corresponding increases in FEV,, PEFR or 
FVC. This may indicate that central deposition is 
more important than peripheral deposition of inhaled 
P2-agonists. Zanen et al. (19) showed that when 
monodispersed salbutamol particles of 1.5 pm were 
inhaled, the bronchodilator response was less than 
when the same asthma patients inhaled particles sized 
2*8,~m. While a higher proportion of the 1.5pm 
particles would have been deposited in the alveoli and 
the existence of P,-adrenoceptors in this region has 
been established, the lack of smooth muscle results in 
reduced bronchodilation. 
Overall, dose and deposition patterns of a 
P,-agonist with corresponding bronchodilation in 
asthma patients have revealed that the response is 
dependent on the amount of drug reaching the lung, 
rather than the distribution. Further data are 
required to determine whether this is the case for 
corticosteroids. Nevertheless, it has been shown that 
inflammation is present throughout the airways in 
asthma (16-18), and thus, widespread deposition of 
inhaled drug in the lung may be required. 
When the fine particle dose contains a majority of 
particles within the 2-5,~rn range, then a fairly even 
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lung distribution will be achieved. Recently, it has 
been shown that there is a link between total lung 
deposition and fine particle dose (22). Thus, the 
potential clinical effect of an inhaled drug can be 
predicted from in vitro measurement of the fine 
particle dose. 
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